Boehringer Ingelheim GmbH, of Ingelheim, Germany, acquired ICD Therapeutics GmbH, of Berlin. The acquisition includes rights to ICD's Macrodel biologics delivery platform. Boehringer will employ that platform for the development of therapeutics in collaboration with Nanopet Pharma GmbH, of Berlin, a former shareholder of ICD. Further details of the acquisition were not disclosed.